LCB33 / LigaChem Biosci - LARVOL DELTA

A novel small molecule inhibitor of ENPP1 promotes T and NK cell activation and enhances anti-tumor efficacy in combination with immune checkpoint blockade therapy (AACR 2023) - "The in vivo anti-tumor efficacy of our compound was assessed by monitoring tumor growth in CT-26 syngeneic mouse model. LCB33 ENPP1 inhibitor shows excellent ENPP1 inhibitory activity at an IC50 of 0.9nM and 1nM in enzyme assay using pNP-TMP and cGAMP as substrates, respectively... Taken together, we report a novel and potent small molecule ENPP1 inhibitor in this study. Our ENPP1 inhibitor showed immune-cell mediated anti-cancer effects without affecting T cell proliferation. Additionally, we confirmed that our compounds showed synergistic anti-cancer effect with immune checkpoint blocker, anti-PD-L1, in colon-cancer mouse model."

Checkpoint block • Checkpoint inhibition • Clinical • Combination therapy • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

24 domestic pharmaceutical companies “Let’s go to AACR”… K-Bio, candidate material ’show off’ (Medi-consumer News) - "Hanmi Pharmaceutical plans to introduce the results of its research on six candidate substances from the 17th to the 19th. The antitumor activity of a novel YAP/TAZ-TEAD inhibitor targeting the Hippo pathway in solid cancer and the antitumor effect of HM99462, an SOS1 inhibitor, against KRAS mutant cancer will be explained....LegoChem Bioscience will share the results of research on immuno-anticancer drugs using the low-molecular-weight compound 'LCB33', a new method in which existing immuno-anticancer drugs maximize drug effects by regulating the tumor microenvironment."

Preclinical • Oncology • Solid Tumor